Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Imugene.
RELATED STOCKHEAD STORIES
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX resumes rally on Powell’s remarks; goldies in focus, copper hits 12-month high
News
Market Highlights: Powell’s speech to lift ASX today, and what Tesla’s bad quarter signals to investors
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
ASX Health Stocks: Dimerix ACTION3 Phase 3 interim trial results are out… and they’re good
News
Market Highlights: Lyft stock jumps 35pc, the new Sensational Six, and 5 small caps to watch today
News
In Case You Missed It: A thing, a different thing and an amusing play on words, I guess
Health & Biotech
ASX Health Stocks: Imugene gains on positive early signs from Phase 1 trial
News
Short & Caught: Pilbara Minerals ASX’s most shorted as lithium stocks targeted
Health & Biotech
ASX Health Stocks: Imugene wins ‘intention to grant’ cancer vaccine patent, Phase 2 trial in 2024
News
ASX November winners: The best 50 stocks as cooling inflation gives markets a little reprieve
Health & Biotech
ASX Health Winners: Biotechs up 10pc in November, and Janus Henderson’s prediction for 2024
News
ASX Small Cap Lunch Wrap: It’s a rarity to see so much parity; Cooper’s got new copper
News
Short & Caught: Pilbara Minerals is the ASX’s most shorted as lithium prices tumble
Health & Biotech
Check Up: Imugene’s oncolytic virus VAXINIA granted FDA’s Fast Track, but how effective is this novel therapy?
News
Rise and Shine: Everything you need to know before the ASX opens
News